A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.
A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.
Perrigo Co. said it had previously prevailed in litigation related to the drug’s launch at both the district and appellate levels. The product has begun shipping immediately, according to the company.
Trospium, also marketed under the brand name Sanctura XR, is a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Related Content
PTNS therapy for OAB found durable at 3 years
Newer overactive bladder agent viable alternative to antimuscarinics
Destigmatizing Urology: Dr. Winter discusses STDs/STIs
March 22nd 2022“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.
Researchers advocate ultrasound over CT for initial evaluation of suspected urinary stone disease
November 7th 2022The study authors maintain there is no current evidence in the literature indicating that CT use is superior to other imaging modalities in reducing morbidity or improving outcomes in patients with urinary stone disease.